Achieve Life Sciences, Inc. (ACHV) P/E Ratio History
Deep ValueTrading at -3.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1996–2001
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Achieve Life Sciences, Inc. (ACHV) trades at a price-to-earnings ratio of -3.9x, with a stock price of $4.85 and trailing twelve-month earnings per share of $-0.97.
The current P/E is 104% below its 5-year average of 97.8x. Over the past five years, ACHV's P/E has ranged from a low of 6.7x to a high of 265.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ACHV trades at a 118% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ACHV trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ACHV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ACHV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ACHV P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 197.0 | -Best | -79% | |
| $383B | 91.4Lowest | -Best | -1%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ACHV Historical P/E Data (1996–2001)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2001 Q4 | Dec 31 2001 | $319968.00 | $1450.24 | 220.6x | +126% |
| FY2001 Q3 | Sep 30 2001 | $140580.00 | $9860.00 | 14.3x | -85% |
| FY2000 Q2 | Jun 30 2000 | $138600.00 | $20740.01 | 6.7x | -93% |
| FY1999 Q4 | Dec 31 1999 | $99000.00 | $1008.94 | 98.1x | +0% |
| FY1997 Q4 | Dec 31 1997 | $999999.00 | $3763.90 | 265.7x | +172% |
| FY1997 Q3 | - | $999999.00 | $14383.83 | 69.5x | -29% |
| FY1997 Q2 | Jun 30 1997 | $999999.00 | $31727.95 | 31.5x | -68% |
| FY1997 Q1 | Mar 31 1997 | $999999.00 | $34499.93 | 29.0x | -70% |
| FY1996 Q4 | - | $999999.00 | $6890.24 | 145.1x | +48% |
Average P/E for displayed period: 97.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ACHV — Frequently Asked Questions
Quick answers to the most common questions about buying ACHV stock.
What is ACHV's P/E ratio?
Achieve Life Sciences, Inc. (ACHV) trailing twelve-month P/E ratio is -3.9x, based on TTM diluted EPS of $-0.97. The 5-year average P/E is 97.8x and the historical range spans 6.7x to 265.7x.
Is ACHV stock overvalued or undervalued?
ACHV trades at -3.9x P/E, below its 5-year average of 97.8x. At the 0th percentile of its historical range (6.7x–265.7x), the stock is priced at a discount to its own history.
Is ACHV stock expensive?
No, ACHV is not expensive on a historical basis. The current P/E of -3.9x is below the 5-year average of 97.8x and sits at the 0th percentile of its valuation range.
What is ACHV's historical P/E range?
Over the past 5 years, ACHV's P/E ratio has ranged from 6.7x to 265.7x, with a median of 69.5x and an average of 97.8x. The current P/E of -3.9x places the stock at the 0th percentile of this range. Full historical data spans 1996–2001.
How does ACHV's P/E compare to the S&P 500?
ACHV trades at -3.9x P/E versus the S&P 500 median of 24.4x. The 116% discount to the market suggests lower growth expectations or perceived higher risk.
How does ACHV's valuation compare to Healthcare peers?
Achieve Life Sciences, Inc. P/E of -3.9x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ACHV's PEG ratio?
ACHV PEG ratio is N/A, based on a P/E of -3.9x and EPS growth of -0.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ACHV's earnings yield?
ACHV earnings yield is N/A, the inverse of its -3.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.